Cereno Scientific nominates drug candidate CS585 in PCA Program for continued development in cardiovascular disease
Cereno Scientific (XSAT: CRNO B) today announced that drug candidate CS585 has been nominated for continued development in the preclinical Prostacyclin Analog (PCA) Program after completing initial preclinical studies. The drug candidate was nominated after demonstrating highest potential in cardiovascular disease among a set of similar molecules. CS585 will continue in its preclinical development program with the aim to provide a better treatment for patients with cardiovascular disease.“I am pleased to see a candidate nominated in our PCA Program as it signifies progress and proven